Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: A cross sectional study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Mulder, Sasja F ^a   Bertens, Dirk ^a,b   Desar, Ingrid M E ^a   Vissers, Kris C P ^a   Mulders, Peter F A ^a   Punt, Cornelis J A ^c   van Spronsen, Dick Johan ^d   Langenhuijsen, Johan F ^a   Kessels, Roy P C ^a,b   van Herpen, Carla M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Cognitive function; Executive functioning; Memory and Learning; Sorafenib; Sunitinib; VEGFR TKI

Indexed keywords

BIOLOGICAL MARKER; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXECUTIVE FUNCTION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTELLIGENCE; KIDNEY METASTASIS; MALE; MENTAL CONCENTRATION; PROBLEM SOLVING; TASK PERFORMANCE; TREATMENT DURATION; WORKING MEMORY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MEMORY; MIDDLE AGED; NEOPLASM METASTASIS; NEUROPSYCHOLOGICAL TESTS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 84899091849     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-219     Document Type: Article

References (42)

1. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493. 10.1200/JCO.20.2.485, 11786578.
2. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007, 25:2455-2463. 10.1200/JCO.2006.08.1604, 17485710.
3. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007, 25:3866-3870. 10.1200/JCO.2007.10.8639, 3329758, 17761972.
4. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201. 10.1038/nrc2073, 3329763, 17318212.
5. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005, 438:954-959. 10.1038/nature04481, 16355213.
6. Mateo I, Llorca J, Infante J, Rodríguez-Rodríguez E, Fernández-Viadero C, Peña N, Berciano J, Combarros O. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 2007, 116:56-58. 10.1111/j.1600-0404.2006.00775.x, 17587256.
7. During MJ, Cao L. VEGF, a mediator if the effect of experience on hippocampal neurogenesis. Curr Alzheimer Res 2006, 3:29-33. 10.2174/156720506775697133, 16472200.
8. Cao L, Jliao X, Zuzga DV, Liu Y, Fong DM, Young D, During MJ. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Gen 2004, 36:827-835.
9. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004, 22:2233-2239. 10.1200/JCO.2004.08.094, 15169812.
10. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000, 20:214-232. 10.1016/S0885-3924(00)00199-8, 11018340.
11. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun 2001, 15:371-387. 10.1006/brbi.2001.0643, 11782104.
12. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793. 10.1002/cncr.21234, 15973668.
13. van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 2007, 18:1747-1750. 10.1093/annonc/mdm455, 17890217.
14. Schellekens AF, Mulder SF, van Eijndhoven PF, Smilde TJ, van Herpen CM. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer: two cases. Gen Hosp Psychiatry 2011, 33(83):e1-e3.
15. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma? A prologue. Cancer 2004, 101:466-475. 10.1002/cncr.20393, 15274059.
16. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995, 12:231-235. 10.1016/0169-5002(95)00446-8, 7655832.
17. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008, 110:143-152. 10.1007/s10549-007-9686-5, 3114441, 17674194.
18. Hendriks M, Kessels R, Gorissen M, Schmand B. Neuropsychologische diagnostiek: De Klinische Praktijk 2006, Amsterdam: Boom.
19. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment 2004, Oxford: University Press.
20. Bates ME, Lemay EP. The d2 test of attention: construct validity and extensions in scoring techniques. J Int Neuropsychol Soc 2004, 10:392-400.
21. Mahway NJ. Handbook of psychological assessment in primary care settings 2000, Mahwah: Lawrence Erlbaum Associates.
22. Zimmermann P, Fimm B. TAP: tests of Attentional Performance (version 2.1 Operation Manual) 2007, Herzogenrath: Psytest.
23. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982, 21:1-16. 10.1111/j.2044-8260.1982.tb01421.x, 7126941.
24. Beck AT, Steer RA, Brown GK. Beck Depression Inventory - Second Edition: Manual 1996, San Antonio, TX: Psychological Corporation.
25. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994, 38:383-392. 10.1016/0022-3999(94)90099-X, 7965927.
26. Ross HA. Gemeten en berekend vrij testosteron. Ned Tijdschr Klin Chem Labgeneesk 2007, 32:38-42.
27. Grebenchtchikov N, Sweep CG, Geurts-Moespot A, Piffanelli A, Foekens JA, Benraad TJ. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods 2002, 268:219-231. 10.1016/S0022-1759(02)00213-2, 12215390.
28. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM, Sweep CG. EORTC receptor and biomarker study group report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 2000, 15:184-191.
29. Warmenhoven F, van Rijswijk E, Engels Y, Prins J, van Weel C, Vissers K. The Beck depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in Dutch advanced cancer patients. Support Care Cancer 2012, 20:319-324. 10.1007/s00520-010-1082-8, 3244603, 21243377.
30. Hermelink K, Kuchenhoff H, Untch M, Bauerfeind I, Lux MP, Bühner M, Manitz J, Fensterer V, Münzel K. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010, 19:1321-1328. 10.1002/pon.1695, 20127909.
31. Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007, 66:108-118. 10.1016/j.pec.2006.11.005, 17320337.
32. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases, involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
33. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastastic renal cell carcinoma. J Clin Oncol 2006, 24:16-24. 10.1200/JCO.2005.02.2574, 16330672.
34. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008, 113:1097-1106. 10.1002/cncr.23658, 18666210.
35. Alibhai SM, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G, Tomlinson G, Fleshner N, Krahn M, Warde P, Canning SD. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 2010, 28:5030-5037. 10.1200/JCO.2010.30.8742, 21041708.
36. Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007, 5:51. 10.1186/1479-5876-5-51, 2169206, 17953739.
37. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002, 86:1396-1400. 10.1038/sj.bjc.6600257, 2375361, 11986770.
38. Wu Y, Fu X, Zhu X, He X, Zou C, Han Y, Xu M, Huang C, Lu X, Zhao Y. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2011, 137:887-896. 10.1007/s00432-010-0951-3, 20878529.
39. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60:644-661. 10.1016/j.eururo.2011.06.041, 21741163.
40. Krogh J, Benros ME, Jørgensen MB, Vesterager L, Elfving B, Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun 2014, 35:70-76.
41. Chang HH, Lee IH, Gean PW, Lee SY, Chi MH, Yang YK, Lu RB, Chen PS. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun 2012, 26(1):90-95. 10.1016/j.bbi.2011.07.239, 21839826.
42. Ng T, Cheung YT, Ng QS, Ho HK, Chan A. Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. Expert Opin Drug Saf 2013, 13(1):83-92.